DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 95 filers reported holding DYNE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,184,253 | -21.2% | 2,364,314 | -1.0% | 0.00% | 0.0% |
| Q2 2023 | $26,873,337 | +61.2% | 2,388,741 | +65.1% | 0.00% | – |
| Q1 2023 | $16,666,641 | -12.6% | 1,446,757 | -12.0% | 0.00% | -100.0% |
| Q4 2022 | $19,058,713 | +12.1% | 1,644,410 | +22.9% | 0.00% | – |
| Q3 2022 | $16,997,000 | +87.3% | 1,338,365 | +1.3% | 0.00% | – |
| Q2 2022 | $9,077,000 | -32.4% | 1,321,225 | -5.2% | 0.00% | – |
| Q1 2022 | $13,437,000 | -18.8% | 1,393,941 | +0.1% | 0.00% | – |
| Q4 2021 | $16,558,000 | -21.2% | 1,392,722 | +7.7% | 0.00% | -100.0% |
| Q3 2021 | $21,003,000 | -17.8% | 1,293,342 | +6.5% | 0.00% | 0.0% |
| Q2 2021 | $25,561,000 | +88.3% | 1,214,883 | +39.0% | 0.00% | – |
| Q1 2021 | $13,573,000 | -6.4% | 873,973 | +26.6% | 0.00% | – |
| Q4 2020 | $14,502,000 | +1497.1% | 690,582 | +1434.6% | 0.00% | – |
| Q3 2020 | $908,000 | – | 45,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $19,891,505 | 30.79% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $44,363,675 | 23.76% |
| Atlas Venture Life Science Advisors, LLC | 9,885,449 | $88,573,623 | 13.72% |
| Logos Global Management LP | 2,180,000 | $19,532,800 | 2.61% |
| TCG Crossover Management, LLC | 1,650,150 | $14,785,344 | 2.18% |
| VR Adviser, LLC | 2,173,913 | $19,478,260 | 2.05% |
| Altium Capital Management LP | 315,000 | $2,822,400 | 1.47% |
| Vivo Capital, LLC | 1,035,136 | $9,274,819 | 1.02% |
| Octagon Capital Advisors LP | 692,945 | $6,208,787 | 0.95% |
| ACUTA CAPITAL PARTNERS, LLC | 146,500 | $1,312,640 | 0.88% |